ERBB2 and breast carcinoma: The prognosis differs between HER2-low and HER2-0 cases (11), and for HER2-low cases, a clinical trial (DESTINY-Breast04) has shown that the anti-HER2 drug trastuzumab deruxtecan is highly effective in metastatic HER2-low breast cancer (12).